Primary prevention of skin dysplasia in renal transplant recipients with photodynamic therapy: A randomized controlled trial

American Journal of Transplantation

Volumn 15, Issue 11, 2015, Pages 2986-2990

  Togsverd Bo, K ^a   Omland, S H ^a   Wulf, H C ^a   Sorensen S S ^a   Haedersdal M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; CYCLOSPORIN; MYCOPHENOLATE MOFETIL; STEROID; TACROLIMUS;

ACTINIC KERATOSIS; ADULT; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; ARTICLE; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG WITHDRAWAL; DYSPLASIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LOW DRUG DOSE; MALE; NON MELANOMA SKIN CANCER; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN DYSPLASIA; STEROID THERAPY; ADVERSE EFFECTS; KAPLAN MEIER METHOD; KERATOSIS, ACTINIC; KIDNEY TRANSPLANTATION; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; PREOPERATIVE CARE; PROCEDURES; REFERENCE VALUE; RISK ASSESSMENT; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; KERATOSIS, ACTINIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; PREOPERATIVE CARE; PRIMARY PREVENTION; REFERENCE VALUES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84945477607     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13358     Document Type: Article

References (22)

1. International Figures of Donation and Transplantation. no-1-september-2013. Available from: http://www.ont.es/publicaciones/Documents/newsletter-transplant-vol-18-no-1-september-2013.pdf. 2014.
2. Zwald FO, Brown M,. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-261.
3. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sorensen HT,. Skin cancer risk among solid organ recipients: A nationwide cohort study in Denmark. Acta Derm Venereol 2010; 90: 474-479.
4. Berman B, Cockerell CJ,. Pathobiology of actinic keratosis: Ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013; 68: S10-S19.
5. Karran P. Thiopurines,. DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 79-80: 153-170.
6. Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN,. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation 2007; 84: 437-439.
7. Slaughter DP, Southwick HW, Smejkal W,. Field cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin. Cancer 1953; 6: 963-968.
8. Basset-Seguin N, Baumann CK, Gerritsen MJ, et al., Photodynamic therapy for actinic keratosis in organ transplant patients. J Eur Acad Dermatol Venereol 2013; 1: 57-66.
9. Zwald FO, Brown M,. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 263-279.
10. Henderson BW, Dougherty TJ,. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-157.
11. Wennberg AM, Stenquist B, Stockfleth E, et al., Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: A randomized study. Transplantation 2008; 86: 423-429.
12. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
13. Togsverd-Bo K, Lerche CM, Poulsen T, Wulf HC, Haedersdal M,. Photodynamic therapy with topical methyl- and hexylaminolevulinate for prophylaxis and treatment of UV-induced SCC in hairless mice. Exp Dermatol 2010; 19: e166-e172.
14. Fitzpatrick TB,. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-871.
15. Wisgerhof HC, Edelbroek JR, de Fijter JW, Feltkamp MC, Willemze R, Bouwes Bavinck JN,. Trends of skin diseases in organ-transplant recipients transplanted between 1966 and 2006: A cohort study with follow-up between 1994 and 2006. Br J Dermatol 2010; 162: 390-396.
16. Bagazgoitia L, Cuevas SJ, Juarranz A, Jaen P,. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144-151.
17. Park MY, Sohn S, Lee ES, Kim YC,. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: A histologic analysis. J Am Acad Dermatol 2010; 62: 85-95.
18. Szeimies RM, Torezan L, Niwa A, et al., Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150-159.
19. de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, Willemze R, Bouwes Bavinck JN,. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: Results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
20. Willey A, Mehta S, Lee PK,. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2010; 36: 652-658.
21. Wulf HC, Philipsen P,. Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy. Br J Dermatol 2004; 150: 143-145.
22. Ibbotson SH,. Adverse effects of topical photodynamic therapy. Photodermatol Photoimmunol Photomed 2011; 27: 116-130.